Literature DB >> 11095952

Anandamide and 2-arachidonoylglycerol inhibit fatty acid amide hydrolase by activating the lipoxygenase pathway of the arachidonate cascade.

M Maccarrone1, S Salvati, M Bari.   

Abstract

Treatment of intact human neuroblastoma CHP100 cells with anandamide (arachidonoylethanolamide, AEA) or 2-arachidonoylglycerol (2-AG) inhibits intracellular fatty acid amide hydrolase (FAAH). This effect was not associated with covalent modifications of FAAH, since specific inhibitors of farnesyltransferase, kinases, phosphatases, glycosyltransferase or nitric oxide synthase were ineffective. Electrophoretic analysis of (33)P-labelled proteins, Western blot with anti-phosphotyrosine antibodies, and glycan analysis of cellular proteins confirmed the absence of covalent modifications of FAAH. The inhibition by AEA was paralleled by an increased arachidonate release, which was not observed upon treatment of cells with linoleoylethanolamide, palmitoylethanolamide, or oleoylethanolamide. Moreover, cell treatment with AEA or 2-AG increased the activity of cyclooxygenase and 5-lipoxygenase, and the hydro(pero)xides generated from arachidonate by lipoxygenase were shown to inhibit FAAH, with inhibition constants in the low micromolar range. Consistently, inhibitors of 5-lipoxygenase, but not those of cyclooxygenase, significantly counteracted the inhibition of FAAH by AEA or 2-AG. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095952     DOI: 10.1006/bbrc.2000.3869

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

2.  Lower brain fatty acid amide hydrolase in treatment-seeking patients with alcohol use disorder: a positron emission tomography study with [C-11]CURB.

Authors:  Laura M Best; Belinda Williams; Bernard Le Foll; Esmaeil Mansouri; Richard P Bazinet; Lin Lin; Vincenzo De Luca; Dina Lagzdins; Pablo Rusjan; Rachel F Tyndale; Alan A Wilson; Christian S Hendershot; Markus Heilig; Sylvain Houle; Junchao Tong; Stephen J Kish; Isabelle Boileau
Journal:  Neuropsychopharmacology       Date:  2020-01-07       Impact factor: 7.853

3.  Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.

Authors:  V Di Marzo; D Melck; P Orlando; T Bisogno; O Zagoory; M Bifulco; Z Vogel; L De Petrocellis
Journal:  Biochem J       Date:  2001-08-15       Impact factor: 3.857

4.  Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol.

Authors:  Nazdar Ghafouri; Gunnar Tiger; Raj K Razdan; Anu Mahadevan; Roger G Pertwee; Billy R Martin; Christopher J Fowler
Journal:  Br J Pharmacol       Date:  2004-10-18       Impact factor: 8.739

Review 5.  Anandamide and vanilloid TRPV1 receptors.

Authors:  Ruth A Ross
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

Review 6.  Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS.

Authors:  N Murataeva; A Straiker; K Mackie
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

7.  Effects of cocaine in 5-lipoxygenase-deficient mice.

Authors:  M Kurtuncu; N Battista; T Uz; A D'Agostino; N Dimitrijevic; N Pasquariello; R Manev; M Maccarrone; H Manev
Journal:  J Neural Transm (Vienna)       Date:  2008-03-10       Impact factor: 3.575

8.  Activation of TRPV1 by Capsaicin or Heat Drives Changes in 2-Acyl Glycerols and N-Acyl Ethanolamines in a Time, Dose, and Temperature Dependent Manner.

Authors:  Meera Manchanda; Emma Leishman; Kishan Sangani; Ali Alamri; Heather B Bradshaw
Journal:  Front Cell Dev Biol       Date:  2021-04-16

Review 9.  Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain.

Authors:  M D Jhaveri; D Richardson; V Chapman
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.